Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

NCT05681039 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG: Tiragolumab
DRUG: Atezolizumab
BEHAVIORAL: Standard of Care
BEHAVIORAL: Questionnaires
RADIATION: Cisplatin
RADIATION: Carboplatin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]